NCT06370000View on ClinicalTrials.gov

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

PHASE4RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 7, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2029

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Oral Azacitidine

Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.

Trial Locations (1)

23298

RECRUITING

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER